Oncolytics Biotech, Inc. Common Shares (ONCY)
Oncolytics Biotech, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Its lead product, reolysin, is an oncolytic virus designed to selectively target and destroy cancer cells while stimulating an immune response. The company’s approach aims to enhance existing cancer treatments and improve patient outcomes. Based in Canada, Oncolytics emphasizes research and development to advance its pipeline of oncolytic virus therapies.
Company News
Oncolytics Biotech is planning a three-arm clinical trial for pancreatic cancer treatment, involving pelareorep in combination with chemotherapy and checkpoint inhibitors, with a planned FDA meeting in November 2025 to discuss study details.
Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Anheuser-Busch and Tesla shares were among the more active stocks on Thursday.
Analysts say these are penny stocks to buy. Do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 995% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.